All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
With its lead candidate AP23573 poised to begin Phase III trials in metastatic sarcoma, Ariad Pharmaceuticals Inc. signed a global development and commercialization partnership for the small-molecule mTOR inhibitor with Merck and Co. Inc. (BioWorld Today)